Streetbeat News

Stock Prices

PDCO

Patterson Companies shares are trading higher despite a Q4 miss.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:41 am

MRK

Merck shares are trading higher after the FDA approved CAPVAXIVE for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:39 am

AVTE

Aerovate Therapeutics shares are trading lower after TD Cowen downgraded the stock from Buy to Hold.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:39 am

BBIO

BridgeBio Pharma has surpassed its interim analysis enrollment target for its Phase 3 FORTIFY study of BBP-418 for Limb-girdle Muscular Dystrophy Type 2I/R9, with top-line results expected in 2025. The company is considering pursuing Accelerated Approval for BBP-418 following recent interactions with the FDA.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:36 am

PHIO

Phio Pharmaceuticals shares are trading higher after the company received a patent in South Korea for the INTASYL RXI-185 compound.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:36 am

ITCI

Intra-Cellular Therapies shares are trading higher after the company announced positive topline results from its second Phase 3 trial evaluating Lumateperone as adjunctive therapy for major depressive disorder, meeting primary and key secondary endpoints.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:35 am

AAPL

DIA

MSFT

QQQ

SPY

On June 17th, U.S. stock markets hit record highs driven by technology stocks, with Apple and Microsoft rebounding. The NY Empire State Manufacturing Index showed improvement. The S&P 500 sectors mostly finished higher, led by industrials, information technology, and consumer discretionary stocks. Asian and European markets also saw gains, while crude oil prices dipped slightly.

Portfolio Pulse from Akanksha Bakshi

June 18, 2024 | 11:35 am

CRMT

America's Car-Mart (NASDAQ:CRMT) reported Q4 earnings per share of $0.06, missing the analyst estimate of $0.89 by 93.26%. Sales were $364.67M, slightly beating the estimate of $361.47M. Compared to last year, EPS decreased by 81.25% and sales decreased by 6.09%.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:34 am

SYRE

Spyre Therapeutics has started dosing healthy volunteers in its first clinical trial of SPY001 for Inflammatory Bowel Disease. Interim pharmacokinetic and safety data are expected by the end of 2024. SPY002 is set to begin first-in-human studies in the second half of 2024. All three next-generation antibodies are on track to be in the clinic within 12 months.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:33 am

ITCI

Intra-Cellular Therapies announced positive topline results from its second Phase 3 trial evaluating Lumateperone as an adjunctive therapy for patients with Major Depressive Disorder. The trial met both its primary and key secondary endpoints.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:32 am